SLE - SYSTEMIC LUPUS ERYTHEMATOSUS
Clinical trials for SLE - SYSTEMIC LUPUS ERYTHEMATOSUS explained in plain language.
Never miss a new study
Get alerted when new SLE - SYSTEMIC LUPUS ERYTHEMATOSUS trials appear
Sign up with your email to follow new studies for SLE - SYSTEMIC LUPUS ERYTHEMATOSUS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Engineered immune cells take on lupus and scleroderma in early trial
Disease control Recruiting nowThis early-stage study tests a new treatment called QT-019C, which uses specially engineered immune cells (CAR T-cells) to target and attack faulty cells that cause autoimmune diseases like lupus, scleroderma, and vasculitis. The treatment is given as a one-time infusion and aims…
Matched conditions: SLE - SYSTEMIC LUPUS ERYTHEMATOSUS
Phase: PHASE1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated May 26, 2026 07:13 UTC
-
Engineered immune cells take on tough lupus in early trial
Disease control Recruiting nowThis study tests a treatment called MB-CART19.1 for people with severe systemic lupus erythematosus (SLE) that has not improved with standard therapies. The treatment uses a patient's own immune cells, modified in a lab to target and attack disease-causing cells. The goal is to r…
Matched conditions: SLE - SYSTEMIC LUPUS ERYTHEMATOSUS
Phase: PHASE1, PHASE2 • Sponsor: Miltenyi Biomedicine GmbH • Aim: Disease control
Last updated May 26, 2026 07:08 UTC
-
Lupus drug belimumab under the microscope: can it prevent organ damage?
Disease control Recruiting nowThis study looks at whether the drug belimumab can prevent serious lupus flares that affect major organs. Researchers will compare about 684 lupus patients who take belimumab with those on standard treatments. The goal is to see if belimumab reduces the risk of severe disease act…
Matched conditions: SLE - SYSTEMIC LUPUS ERYTHEMATOSUS
Sponsor: Biomedical Research Foundation, Academy of Athens • Aim: Disease control
Last updated May 26, 2026 07:06 UTC
-
Immune cell reprogramming offers new hope for lupus patients
Disease control Recruiting nowThis early-stage trial tests a new treatment for adults with severe lupus that hasn't improved with standard therapies. The treatment uses specially engineered immune cells from donated umbilical cord blood to target and calm the overactive immune system. The study will check if …
Matched conditions: SLE - SYSTEMIC LUPUS ERYTHEMATOSUS
Phase: EARLY_PHASE1 • Sponsor: Chengdu Ucello Biotechnology Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 06:53 UTC
-
New drug CC312 tested in severe autoimmune patients
Disease control Recruiting nowThis early-stage study tests the safety of a new drug, CC312, in 6 adults with lupus, myositis, or scleroderma that has not responded to standard treatments. The main goal is to check for side effects, not to cure the disease. Participants receive multiple doses of the drug and a…
Matched conditions: SLE - SYSTEMIC LUPUS ERYTHEMATOSUS
Phase: EARLY_PHASE1 • Sponsor: CytoCares Inc • Aim: Disease control
Last updated May 19, 2026 11:47 UTC
-
New lupus drug candidate enters human safety testing
Disease control Recruiting nowThis early-stage study tests a new drug called CC312 in 32 adults with moderate-to-severe lupus. The main goal is to see if the drug is safe and how the body handles it. Participants will receive either the drug or a placebo, and researchers will monitor side effects and drug lev…
Matched conditions: SLE - SYSTEMIC LUPUS ERYTHEMATOSUS
Phase: PHASE1 • Sponsor: CytoCares Inc • Aim: Disease control
Last updated May 15, 2026 11:56 UTC